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Abstract
Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) is a major 
resistance factor for the tumor necrosis factor-related apoptosis-inducing ligand TRAIL and in 
drug resistance in human malignancies. c-FLIP is an antagonist of caspases-8 and -10, which 
inhibits apoptosis and is expressed as long (c-FLIPL) and short (c-FLIPS) splice forms. c-FLIP is 
often overexpressed in various human cancers, including breast cancer. Several studies have 
shown that silencing c-FLIP by specific siRNAs sensitizes cancer cells to TRAIL and anticancer 
agents. However, systemic use of siRNA as a therapeutic agent is not practical at present. In order 
to reduce or inhibit c-FLIP expression, small molecules are needed to allow targeting c-FLIP 
without inhibiting caspases-8 and -10. We used a small molecule inhibitor of c-FLIP, 4-(4-
chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH), and show that CMH, but not its inactive 
analog, downregulated c-FLIPL and c-FLIPS mRNA and protein levels, caused poly(ADP-ribose) 
polymerase (PARP) degradation, reduced cell survival, and induced apoptosis in MCF-7 breast 
cancer cells. These results revealed that c-FLIP is a critical apoptosis regulator that can serve as a 
target for small molecule inhibitors that downregulate its expression and serve as effective 
targeted therapeutics against breast cancer cells.
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Introduction
A key inhibitor of death receptor signaling is c-FLIP, which is expressed in various cancers. 
c-FLIP is expressed as 55-kDa long (c-FLIPL) and 26-kDa short (c-FLIPS) splice forms and 
is an antagonist of caspases-8 and -10 that inhibits apoptosis downstream of the death 
receptors TNF-receptor 1, Fas, DR4, DR5, and FADD [1–3]. Moreover, c-FLIP expression 
is associated with enhanced tumorgenicity and poor clinical outcome in various cancers 
because it plays a major role in chemotherapeutic drug and TRAIL resistance [3–10]. 
Previous studies have revealed that high c-FLIP expression is associated with unresponsive 
tumors, and downregulating its expression should be considered for death receptor targeted 
and chemotherapy [3, 11–13]. c-FLIP isoforms contain two N-terminal DED domains, but 
only c-FLIPL contains a C-terminal caspase domain with structural similarity to caspase-8. 
In the caspase-like domain of c-FLIPL, the catalytically active cysteine is replaced by 
tyrosine, rendering the molecule proteolytically inactive [14]. c-FLIP isoforms are recruited 
to the DISC by their DED domains and compete with the initiator caspases for FADD 
binding sites [3, 10, 15]. c-FLIPS inhibits death signaling at the DISC by inhibiting 
caspase-8 and -10 activation [3, 16]. At high concentration in the cells, the function of c-
FLIPL at the DISC can be anti-apoptotic like c-FLIPS, but at low levels it acts pro-
apoptotically by directly heterodimerizing and activating caspase-8 [17–21]. The pro-
apoptotic function of c-FLIP is supported by studies showing that c-FLIP-deficient mice die 
early in embryonic development due to heart failure, which is a defect also seen in 
caspase-8- and FADD-deficient mice [22,–23]. However, many studies in various cancer 
types have found that the role of c-FLIPL is generally anti-apoptotic in cancer cells. 
Importantly, we [24] and others [12, 25, 26] have shown that silencing of c-FLIP expression 
using small interfering RNAs (siRNAs) promotes spontaneous apoptosis in breast cancer, 
colorectal, lung, and lymphoma cancer cell lines, and augments TRAIL-, anti-DR5 
monoclonal antibody-, and drug-induced apoptosis in various cancer cell types [12, 25–29]. 
We recently discovered that c-FLIPL interacts with DR5, FADD, and caspase-8 forming an 
apoptotic inhibitory complex (AIC) in MCF-7 breast cancer cells [24]. Moreover, silencing 
the c-FLIP gene by a specific siRNA leads to death ligand-independent but DR5-, FADD-, 
and caspases-8- and -9-dependent apoptosis in these cells. Furthermore, we showed that the 
knockdown of c-FLIP expression triggers spontaneous apoptosis by activating both the 
death receptor and mitochondrial pathways and inhibiting breast cancer cell proliferation 
[24]. Moreover, a recent report identified a checkpoint of the autophagy pathway where 
cellular and viral FLIPs could limit the Atg3-mediated step of LC3 ubiquitin-like protein 
conjugation to regulate autophagosome biogenesis. Furthermore, the FLIP-derived short 
peptides induced growth inhibition and cell death with autophagy by binding to and 
effectively suppressing Atg3-FLIP interaction, representing new agents as potential anti-
cancer therapies [30].
In addition to c-FLIP’s key role in preventing apoptosis, c-FLIP variants have also been 
shown to be involved in proliferation, cell cycle progression, and carcinogenesis. The 
overexpression of c-FLIPL inhibited the proteosomal degradation of β-catenin, and the 
elevated β-catenin levels were shown to either promote Wnt signaling or induce cyclin D 
expression, leading to the proliferation and cell cycle progression of cancer cells [31, 32]. In 
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both studies, the c-FLIP/β-catenin signals contributing to cell growth were reversed by the 
selective silencing of c-FLIP expression. Recent results also suggest a role for nuclear c-
FLIPL in modulating Wnt signaling [33]. Caspase-8-dependent cleavage of c-FLIP has been 
shown to produce an N-terminal p22 fragment that directly induced NFκB activation and 
promoted the proliferation of lymphocytic cells [34]. Furthermore, several studies have 
shown that c-FLIP overexpression can promote carcinogenesis and aggressiveness of 
endometrial and cervical cancers [3, 35–38]. These studies highlight the functional 
importance of c-FLIP in the proliferation of cancer cells.
Inhibition of c-FLIP either by compounds that degrade it or c-FLIP-specific small 
interfering RNA (siRNA) sensitizes a wide range of cancer cell types to TNF-related 
apoptosis-inducing ligand (TRAIL) and chemotherapy-induced apoptosis [3, 11–13, 27, 39]. 
We recently reported that an apoptotic inhibitory complex (AIC) comprised of DR5, FADD, 
caspase-8, and c-FLIPL exists in MCF-7 cells, and the absence of c-FLIPL from this 
complex induces ligand-independent caspase-8 activation in the death-inducing signaling 
complex (DISC), leading to apoptosis [24]. These results clearly show that c-FLIP prevents 
death signaling in MCF-7 cells. Similarly, ectopic expression of c-FLIP variants decreased 
apoptosis caused by anticancer agents [3, 12, 13, 16], indicating that over-expression of 
these proteins may cause resistance to multiple anticancer drugs. Therefore, c-FLIP is a 
critical apoptosis regulator that can serve as a target for small molecule inhibitors that 
downregulate its expression and serve as effective targeted therapeutics for cancer treatment. 
In oder to support this hypothesis, our in vivo results showed that injecting liposomal 
complexes of c-FLIP-specific siRNA into MCF-7 xenografts eliminated the neoplastic cells 
without affecting the normal stromal and fibroblastic cells [28].
There does not appear to be a “handle” to inhibit c-FLIP function with small molecule 
ligands since as mentioned above, c-FLIP has significant structural similarity to caspase-8 
[3]. This resemblance with caspase-8 makes c-FLIP protein a very difficult target for drugs 
to inhibit its function, since small molecules capable of blocking c-FLIP’s recruitment to the 
DISC could also inhibit the recruitment of caspase-8 and as a result inhibit apoptosis. 
Therefore, to reduce or inhibit c-FLIP expression, small molecules which target c-FLIP 
without inhibiting caspases-8 and -10 are needed. Employing a high-throughput chemical 
screening strategy, a small molecule inhibitor of c-FLIP, 4-(4-chloro-2-methylphenoxy)-N-
hydroxybutanamide (CMH) (5809354), that downregulates c-FLIP mRNA expression has 
been identified [40, 41]. Our results show that CMH, but not its inactive analog 4-(4-
chloro-2-methylphenoxy)-N-(3-ethoxypropyl) butanamide (CMB) (6094911), 
downregulates c-FLIPL and c-FLIPS mRNA and protein levels in MCF-7 cells, caused 
PARP degradation, reduced cell survival, and induced apoptosis.
Materials and methods
Cell culture, materials, reagents and antibodies
The MCF-7 human breast cancer cell lines were obtained from American Type Culture 
Collection (ATTC, Manassas, VA). MCF-7 human breast cancer cells were maintained in 
RPMI 1640 medium containing 10% fetal calf serum (FCS) and 100 ng/ml each of penicillin 
and streptomycin (Invitrogen, Carlsbad, CA) at 37°C in 5% CO2. The MCF-7 multidrug 
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resistant variant MCF-7/ADR20 cells were selected for resistance to increasing 
concentrations of doxorubicin (DOX) in the growth medium. These cells were maintained in 
10 nM DOX and kept in the growth medium without DOX 1–2 weeks before performing 
experiments.
4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) (5809354) and its inactive 
analog 4-(4-chloro-2-methylphenoxy)-N-(3-ethoxypropyl) butanamide (CMB) (6094911) 
were purchased from ChemBridge Corporation (San Diego, CA). Stock solutions (50 mM) 
of these agents were prepared in dimethyl sulfoxide (DMSO) and stored at 4°C in 
polystyrene tubes. The final concentration of DMSO in growth medium for survival and 
apoptosis assays was less than 0.05%.
The following primary antibodies were used: anti-c-FLIP clone G-11 (Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-c-FLIP clone Dave-2 (ProSci, Poway, CA), anti-DR5 
clone B-D37 (IgG2b), anti-Bcl-2 antibody, anti-PARP antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-DR5 (Cell Signaling Technology, Danvers, MA), anticaspase-8 clone 
3-1-9 (BD Biosciences, San Jose, CA), and anti-β-actin clone AC-74 (Sigma-Aldrich, St. 
Louis, MO).
Western blotting
Cells were harvested, rinsed in cold PBS, and lysed in an M-PER (Pierce Biotechnology, 
Rockford, IL) containing 1% protease inhibitor cocktail (Sigma-Aldrich). Protein 
concentration was determined using the BCA/Cu2SO4 protein assay (Sigma-Aldrich) as 
described by the manufacturer. Protein lysates (70 μg) were separated on a 10% Bis–Tris gel 
(Invitrogen) and transferred to an Immobilon-P membrane (Fisher Scientific, Pittsburgh, 
PA). Membranes were incubated in blocking buffer (PBS, 0.05% Tween 20, 5% skim milk) 
with specific antibodies, followed by the addition of horseradish peroxidase-conjugated 
sheep anti-mouse or anti-rabbit secondary antibodies (Amersham Biosciences, Piscataway, 
NJ). For detecting the anti-c-FLIP clone Dave-2 antibody, a horseradish peroxidase-
conjugated goat anti-rat secondary antibody was used (Santa Cruz Biotechnology).
Detection of apoptosis by DAPI staining
DAPI staining was performed on untreated and CMH-treated MCF-7 cells as described 
previously (42). Briefly, prior to staining, the cells were fixed with 4% paraformaldehyde 
for 30 min at RT. After washing with PBS by centrifugation at 650×g, DAPI was added to 
the fixed cells for 5 min, and then the cells were examined by fluorescence microscopy. 
Apoptotic cells were identified by condensation and fragmentation of nuclei. A minimum of 
300 cells were counted for each treatment, and the percentage of apoptotic cells was 
calculated as the ratio of apoptotic cells to total cells counted × 100. The DAPI staining 
experiments were performed in triplicate.
Determination of apoptosis and cell death using annexin V and propidium iodide staining
Cells were plated at a density of 2 × 105 cells/ml and treated with 30–100 μM CMH for 48 
h, harvested, and stained with fluorescein isothiocyanate-labeled annexin V (BD 
Biosciences) and propidium iodide according to the manufacturer’s protocol. Cells were 
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analyzed using FAC-Scan (BD Biosciences) flow cytometer and CellQuest software (BD 
Biosciences). Apoptotic and necrotic cells were analyzed by quadrant statistics on the 
propidium iodide-positive, annexin V-positive, and the propidium iodide-negative and 
annexin V-positive cells, respectively.
Effects of the general caspase inhibitor z-VAD-fmk on CMH-induced apoptosis
MCF-7 cells (2 × 104/well in 8-well glass slide) were pretreated with or without 100 μM z-
VAD-fmk for 2 h. After that cells were grown in the presence of 10–100 μM PMH at 37°C 
for 48 h. Numbers of apoptotic cells in the z-VAD-fmk treated and control untreated cells 
were determined by DAPI staining as described.
RNA isolation and RT-PCR analysis
Total RNA from treated and untreated MCF-7 cells was isolated by Tri Reagent TR-118 
(Molecular Research Center, Cincinnati, OH) as described by the manufacturer. One 
microgram of total RNA was used in reverse transcription reactions with M-MLV reverse 
transcriptase and oligo (dT) 15 primer (Promega, Madison, WI) as described by the 
manufacturer. Two microliters of the resulting total cDNA were then used as the template in 
PCR to measure the mRNA level of interest by using following primers: for c-FLIPL 
forward, 5′-GCTGAAGTTATCCATCAGGT-3′; reverse, 5′-
CATACTGAGATGCAAGAATT-3′; a 840-bp band was produced. For c-FLIPS, the 
forward primer was the same as c-FLIPL; reverse, 5′-GATCAGGACAATGGGCATAG-3′; 
a 662-bp band was produced. For β-actin, the forward primer was 5′-
CAGAGCAAGAGAGGCATCCT-3′; reverse 5′-TTGAAGGTCTCAAACATGAT-3′; these 
produce a 200-bp band. The reactions were performed at 94°C for denaturation, 58°C for 
annealing, and 72°C for extension for 30 cycles. β-Actin mRNA levels were used as internal 
controls. The amplified fragments were separated on 1.5% agarose gels and visualized by 
ethidium bromide staining.
Statistical analysis
Data are expressed as the mean ± standard deviation (SE). The statistical significance of 
intergroup differences was determined using Student’s t test. P values <0.05 were 
considered statistically significant.
Results
CMH induces robust apoptosis
We used the small molecule inhibitor of c-FLIP, CMH, and showed that CMH, but not its 
inactive analog CMB (Fig. 1a), robustly reduces cell survival, but the inactive analog had 
little effect on cell survival (Fig. 1b). The concentration of the drug that reduced cell 
survival by 50% (IC50 value) in MCF-7 cells was obtained from the CMH dose–response 
curves using methylene blue cytotoxicity assay after 72-h treatment with increasing 
concentrations of the drug; the IC50 was approximately 30 μM. We also determined whether 
CMH inhibits cell survival in MCF-7/ADR20, a drug resistant variant of MCF-7 which 
expresses 20-, 2.5-, and 1.9-fold resistance to DOX, Taxol, and vincristine, respectively. The 
data shown in Fig. 1c demonstrate that CMH had even a greater inhibitory effect on cell 
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survival in these drug resistant cells. The IC50 value for 72 h treatment with CMH for 
MCF-7/ADR20 was 10 μM.
Next, we determined the levels of CMH-induced apoptosis in MCF-7 cells by DAPI 
staining. Apoptotic cells were identified by condensation and fragmentation of nuclei. The 
data shown in Fig. 2a clearly show CMH induced apoptosis visualized by DAPI staining of 
MCF-7 cells treated with 10–100 μM CMH. Quantitation of apoptosis assessed by DAPI 
staining revealed that treating the cells with 10–100 μM for 48 h induced 5–28% apoptosis, 
compared to untreated MCF-7 cells (Fig. 2a). Similar results were obtained when apoptosis 
was quantified by annexin V binding assay (Fig. 2b). Moreover, treating the cells with 100 
μM of the general caspase inhibitor z-VAD-fmk for 48 h significantly inhibited CMH-
induced apoptosis as shown in Fig. 3A and B.
CMH inhibits mRNA expression of c-FLIPL and c-FLIPS variants
In order to determine if the CMH-mediated decrease in c-FLIP variant expression occurred 
at the mRNA level, semiquantitative RT-PCR was performed as we previously described 
(16). After treating MCF-7 cells with 10–100 μM CMH for 72 h, a dose-dependent decrease 
in c-FLIPS transcript level was observed (Fig. 4a–c). Moreover, treatment with 50 and 100 
μM CMH for 72 h very effectively decreased the c-FLIPL transcript level (Fig. 3A–C). Our 
data clearly showed that CMH mediated the reduction of both c-FLIP variants at the mRNA 
level.
The molecular mechanism by which CMH downregulates c-FLIPL and c-FLIPS mRNA in 
MCF-7 cells is not known. Therefore, we investigated whether CMH-induced 
downregulation of c-FLIPL and c-FLIPS occurs at the transcription level or by altering the 
stability of their mRNA. We treated the cells with the transcription inhibitor actinomycin D, 
or actinomycin D plus CMH, as described in the legend of Fig. 5a and b. In order to 
suppress apoptosis while inhibiting mRNA expression with actinomycin D or actinomycin D 
plus CMH, we pre-treated the cells with 100 μM of the general caspase inhibitor z-VAD-
fmk in DMSO for 2 h and collected them after 6, 12, and 22 h of treatment. RNA from these 
samples was then prepared, and semiquantitative RT-PCR analysis of c-FLIPL and c-FLIPS 
mRNA expression was carried out as previously described [16]. Our mRNA analysis 
showed that actinomycin D treatment inhibited c-FLIPL and c-FLIPS mRNA expression by 
about 50% after 22 h treatment. Further-more, mRNA levels in the cells treated with 
actinomycin D plus CMH were similar to the level of mRNA in the cells treated with 
actinomycin D alone (Fig. 5a, b). These data and the results shown in Fig. 4a indicate that 
CMH inhibits c-FLIPL and c-FLIPS mRNA expression at the transcription level and does 
not affect c-FLIPL mRNA stability.
CMH inhibits expression of c-FLIPL and c-FLIPS variants at the protein level
The results of Western blot analysis corroborated our RT-PCR data and showed that treating 
MCF-7 cells with 10–100 μM CMH for 72 h reduced levels c-FLIPS and c-FLIPL in MCF-7 
cells (Fig. 6a). In order to determine whether CMH only affects c-FLIP variants or it inhibits 
expression of another anti-apoptotic protein, we treated the cells with 10–100 μM CMH for 
72 h and performed Western blotting to detect BCL-2 expression. These results were 
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consistent with degradation of poly(ADP-ribose) polymerase (PARP) as shown in Fig. 6b. 
The results in Fig. 6b clearly show that CMH treatment did not affect the expression of 
BCL-2.
Discussion
The overexpression of c-FLIP variants in tumor cells is a determinant of resistance to death 
ligands such as TRAIL and many chemotherapeutic agents in variety of tumors [3]. 
Moreover, silencing c-FLIP variants with specific siRNAs has sensitized various resistant 
tumor cells from different types of cancer to these agents [18, 19, 26, 27, 43]. However, in 
vivo use of siRNA as a systemic therapeutic agent is not feasible because of the lack of 
appropriate delivery vehicles into the cells. Therefore, agents causing degradation of c-FLIP 
at the protein level or therapeutics that directly target c-FLIP mRNA are potentially useful 
modalities for treating tumors resistant to cytokines and chemotherapeutic agents. Moreover, 
our previous results [28] and the current understanding of c-FLIP action in normal tissues 
[15, 44, 45] support the notion that c-FLIP-targeted cancer therapy will be well tolerated. 
However, it is not possible to inhibit c-FLIP function with small molecule ligands, since the 
cytoprotective DISC binding is mediated by highly conserved DEDs which function by 
homotypic binding. However, a small molecule CMH (5809354) that induces c-FLIP 
downregulation and sensitize neoplastic cells to apoptosis induction by the cytokine TRAIL 
have been identified in global, unbiased chemical screens [40]. CMH causes anoikis in 
PPC-1 prostate cancer cells cultured in suspension but not in adherent cultures [41]. In order 
to downregulate c-FLIP variants expression at the mRNA level and trigger apoptosis in 
MCF-7 and MCF-7/ADR20 cells, we used CMH, which has been shown to sensitize cells to 
Fas and mediated anoikis [41].
We found that CMH decreased c-FLIPL and c-FLIPS mRNA and protein expression and 
thereby sensitized MCF-7 and MCF-7/ADR20 cells to apoptosis. A previous report showed 
that CMH was only able to cause anoikis in PPC-1 prostate cancer cells cultured in 
suspension and did not affect the adherent cells [41]. However, our previous data using c-
FLIPL-specific siRNA [24] and the data shown here using CMH demonstrated that these 
agents induce apoptosis in adherent cells as well. In this study, we also investigated 
mechanism by which CMH downregulates c-FLIPL and c-FLIPS at the mRNA level. Our 
data suggest that CMH decreased transcription of the c-FLIPL and c-FLIPS mRNA.
We also investigated the apoptosis mechanism by which decreased the level of c-FLIPL and 
c-FLIPS sensitized cells. We found that CMH at lower concentrations (10–30 μM) caused 
little inhibition of the c-FLIP variants while it decreased cell survival and caused cell death. 
Moreover, CMH triggered more cell death in the resistant variant compared to sensitive 
MCF-7 cells at these concentrations. However, CMH-induced cell death occured via a 
caspase 8-dependent mechanism only at 100 μM. Moreover, PARP degradation was 
observed at 50 and 100 μM CMH treatment. Our data collectively suggest that at 10–30 μM, 
CMH induced inhibition of cell survival by a mechanism(s) independent of c-FLIP variants 
expression.
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To our knowledge, this study is the first to show that (a) malignant breast cancer cells can 
undergo apoptosis when expression of c-FLIPL and c-FLIPS variants is decreased by the 
small molecule inhibitor CMH and (b) CMH downregulates c-FLIPL and c-FLIPS at the 
transcriptional level and by decreasing the stability of RNA, respectively. In summary, our 
data suggest that downregulation of c-FLIPL and c-FLIPS by the small molecule inhibitor 
CMH causes inhibition of cell survival and triggers cell death. Since c-FLIP variants are 
master regulators of cell survival and apoptosis, as well contributing to cell proliferation and 
metastasis, inhibiting the expression of c-FLIP variants by small molecule inhibitors such as 
CMH may provide a useful strategy to treat malignancies.
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Fig. 1. 
CMH but not its inactive analog (CMB) robustly inhibited cell survival in MCF-7 breast 
cancer cell line. a Chemical structures of 4-(4-chloro-2-methylphenoxy) N-
hydroxybutanamide (CMH) and its inactive analog 4-(4-chloro-2-methylphenoxy) N-(3-
ethoxypropyl) butanamide (CMB). b MCF-7 or c MCF-7/ADR20 cells were treated with 
10–100 μM of CMH or its inactive analog CMB for 72 h. After harvesting the cells, survival 
was determined by cell survival assay. For each treatment, 1 × 104 cells were seeded in a 96-
well plate and treated with or without CMH. Cells were stained with 1% methylene blue in 
50% methanol. After the plates were washed by immersing in dH2O, and excess of water 
was removed the dye was dissolved in 100 μl of 0.5 M HCl. Absorbance was determined by 
an automated scanning photometer at a wavelength of 630 nm. The results were obtained 
from triplicate experiments. Percent inhibitions of cell survival by various CMH 
concentrations compared to the control untreated cells (0) ± SD are shown (P < 0.001)
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Fig. 2. 
CMH triggered dose-dependent apoptosis in MCF-7 breast cancer cells. a MCF-7 cells were 
treated with 10–100 μM of CMH for 48 h and apoptotic cell death was determined by DAPI 
staining as previously described [42]. Apoptotic cells were identified by condensation and 
fragmentation of nuclei. A minimum of 300 cells were counted for each treatment, and the 
percentage of apoptotic cells was calculated. b Apoptosis was determined by FACScan 
analysis as described under “Materials and methods” section. Compensation was executed 
for each experiment using untreated cells stained with Annexin V and propidium iodide. 
Experiments were performed in triplicate. Error bars show SD from triplicate measurements 
(P < 0.005)
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Fig. 3. 
CMH triggered caspase-dependent apoptosis in MCF-7 breast cancer cells. DAPI staining 
was carried out as described in “Materials and methods” section. A fluorescence microscopy 
of untreated (a), 50 and 100 μM CMH treated (b, c), MCF-7 cells compared with z-VAD-
fmk pre-treated (d), plus 50 and 100 μM CMH treated (e, f) cells for 48 h. B Apoptosis was 
quantified by counting fragmented nuclei and condensed stained among 300 cells from the 
control, z-VAD-fmk, and cells treated with 10–100 μM CMH. Data are average of triplicate 
experiments (** P < 0.01)
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Fig. 4. 
CMH-induced decrease of c-FLIPS and c-FLIPL levels occurs at the mRNA level. a MCF-7 
cells were treated without (0) or with 10–100 μM CMH for 72 h, and the total RNA was 
isolated for semiquantitative RT-PCR as we previously described (2). Equivalent addition of 
RNA was confirmed by PCR analysis of β-actin. (b, c) c-FLIPS and c-FLIPL mRNA 
expression relative to β-actin expression shown in panel (a) was quantified using Image J 
1.37c software. Data are average of triplicate measurements (** P < 0.05)
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Fig. 5. 
Densitometric analysis of semiquantitative RT PCR of c-FLIPL (a) and c-FLIPS mRNA (b) 
expression following treatment with actinomycin D or actinomycin D plus CMH for 22 h. c-
FLIPL and c-FLIPS gene expression were measured in MCF-7 cells treated with 5 μg/ml 
actinomycin D for the times indicated in the presence or absence of 50 μM CMH. In order to 
prevent apoptosis, cells were pretreated for 2 h with the 100 μM of the general caspase 
inhibitor z-VAD-fmk. Results show that while the stability of c-FLIPL mRNA is not 
affected by CMH, it decreases the stability of c-FLIPS mRNA. mRNA expression was 
normalized to β-actin mRNA levels. Data are average of triplicate measurements (** P < 
0.005)
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Fig. 6. 
Western blot analysis of c-FLIPS, c-FLIPL, PARP, and BCL-2 in MCF-7 cells treated with 
CMH. Cell lysates (70 βg protein/lane) from MCF-7 cells treated without (0) or with 10, 30, 
50, and 100 βM CMH were subjected to SDS polyacrylamide gel electrophoresis (PAGE) 
and Western blot analysis using a an anti-c-FLIP antibody (Cell Signaling Technology, 
Danvers, MA) and b anti-PARP antibody, anti-BCL 2 antibody, as well as anti-GAPDH 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
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